Is DGX stock a Buy, Sell, or Hold?

Based on our analysis, DGX is currently a WAIT with low confidence. 📊 MIXED SIGNALS: DGX shows conflicting indicators. Wait for confirmation before entering.

What is the fair value of DGX stock?

Our analysis estimates the fair value range for DGX to be between $215.18 and $241.26. The current price is $244.39.

What is the analyst price target for DGX?

The average Wall Street analyst price target for DGX is $245.87. This implies a potential upside of 0.6% from current levels.

DGX Stock Analysis: Buy, Sell, or Hold?

DGX - Quest Diagnostics Inc.

SERVICES-MEDICAL LABORATORIES

$244.39

3.09 (1.28%) ▲

5d: +4.26%

30d: +7.24%

90d: +26.09%

WAIT

LOW Confidence

Protect Your DGX Gains

Analysis Updated: Aug 21, 2026 12:00 AM ET

Earnings: Oct 20, 2026

Smart Money Accumulation

Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →

Signal fired Aug 20, 2026 at $241.30 · last confirmed Aug 21, 2026

Strength: 4.6/10

Get Alerted When DGX Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
📊 MIXED SIGNALS: DGX shows conflicting indicators. Wait for confirmation before entering.

See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 7.7%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$281.88

Based on 5.9% avg growth

INTRINSIC VALUE TODAY

$175.03

Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.6x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: DGX is currently trading at $244.39, which is considered extended relative to its 30-day fair value range of $215.18 to $241.26. From a valuation perspective, the stock is trading at a premium (Forward PE: 20.3) compared to its historical average (17.6). At these levels, the market is pricing in 4.8% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.

Technical Outlook: Technically, DGX is in a strong uptrend. The price is approaching resistance at $245.68. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.

Market Sentiment: The stock scores a mixed 46/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position EXTENDED

Historical Trading Range $215.18 - $241.26

Company Quality Score 49/100 (HOLD)

Volume Confirmation HIGH

Confidence Score 45.2%

Protect Your Profits

DGX is technically overbought (RSI 75). Consider hedging now to protect against a potential pullback while keeping your upside.

View Profit Protection Plan

All Signals

BEARISH: Price extended above range
NEUTRAL: Mixed technical signals (46/100)
BULLISH: High volume confirmation
NEUTRAL: Near Wall St target ($245.87)
NEUTRAL: Trading at premium valuation - market expects 4.8% growth which is achievable
WARNING: Composite score 49/100 in the bottom quintile — this cohort historically lags the market

Trading Range Analysis

30-Day Trading Range $215.18 - $241.26

Current vs Trading Range EXTENDED

Support & Resistance Levels

Support Level $232.28

Resistance Level $245.68

Current Trend Strong Uptrend

Technical data as of Aug 21, 2026

Fundamental Context

Forward P/E (Next Year Est.) 20.27

Wall Street Target $245.87 (+0.6%)

Revenue Growth (YoY) 10.2%

Earnings Growth (YoY) 15.0%

Profit Margin 9.2%

Valuation Premium vs History +4.8% premium

PE vs Historical 20.3 vs 17.6 STRETCHED

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): +4.8% (market-implied from PE analysis)

1-Year Target $256.12 (+5%)

2-Year Target $268.41 (+10%)

3-Year Target $281.30 (+15%)

3-Yr Target (if PE normalizes) (PE: 20→18) PE COMPRESSION $244.26 (0%)

Earnings growth offset by PE compression

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 20.3, Growth: 7.7%) $305.62 (+25%)

Base: (SPY PE: 20.1, Growth: 7.7%) $302.63 (+24%)

Bear: (PE: 17.1, Growth: 7.7%) $257.23 (+5%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (26x PE), but valuation improves significantly next year (20x PE) as earnings recover.

Trailing PE: 25.64 | Current EPS (TTM): $9.41

Bull Case $340.11 (+39%)

Analyst growth 28.1%, PE expands to 28.2

Base Case $309.19 (+27%)

Market implied 28.1%, PE stable at 25.6

Bear Case $164.08 (-33%)

Severe decline -20.0%, PE contracts to 21.8

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: August 24, 2026 8:00 AM ET
Data refreshes hourly during market hours. Next update: 9:00 AM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is DGX showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

INSIDERS SELLING

Recent Transactions

Michael E Prevoznik SELL 3878 shares 2026-03-05

Patrick Plewman SELL 2855 shares 2026-03-05

Catherine T Doherty SELL 5558 shares 2026-03-05

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for DGX.

Create Free Account

Already have an account? Log In

Top Rated Diagnostics & Research Stocks

Top-rated stocks in Diagnostics & Research by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
TMO Thermo Fisher Scientific…	STRONG BUY 31 analysts	$631	41 HOLD
EXAS EXACT Sciences Corporati…	STRONG BUY 26 analysts	$106	52 HOLD
GH Guardant Health Inc	STRONG BUY 23 analysts	$194	50 HOLD
DHR Danaher Corporation	STRONG BUY 25 analysts	$228	43 HOLD
NTRA Natera Inc	STRONG BUY 21 analysts	$337	38 SELL

TMO Thermo Fisher Sci…

41 HOLD

EXAS EXACT Sciences Co…

52 HOLD

GH Guardant Health I…

50 HOLD

DHR Danaher Corporati…

43 HOLD

NTRA Natera Inc

38 SELL

Advanced DGX Option Strategies

Professional options setups generated by AI based on today's DGX price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for DGX

DGX Technical Chart DGX Price Prediction DGX Earnings Date DGX Investment Advisor DGX Fair Price Analyzer DGX Options Advisor DGX Options Chain DGX Options Analysis DGX Competitors

Compare DGX with Peers

DGX vs LH
Which one to buy?

DGX vs DVA
Which one to buy?

DGX vs BDX
Which one to buy?

DGX vs UHS
Which one to buy?

DGX vs CAH
Which one to buy?

DGX vs A
Winner: A

WAT vs DGX

EXAS vs DGX

GH vs DGX
Winner: DGX

DGX vs RDNT
Winner: DGX

Create New Comparison View All Competitors

Tradestie